Enterococcus species inhabit the human gastrointestinal tract and may be recovered from urine, wounds, abdominal specimens, and blood. Their isolation raises a recurring clinical question: does the organism represent harmless colonization, contamination, or a causative pathogen requiring treatment? This narrative review synthesizes contemporary clinical guidelines and selected studies, emphasizing practical interpretation across specimen types, species-level identification, and antimicrobial stewardship. Enterococcus faecalis and Enterococcus faecium differ substantially in epidemiology, antimicrobial susceptibility, and association with healthcare exposure. Asymptomatic bacteriuria generally should not be treated, except during pregnancy or before selected endourological procedures associated with mucosal trauma. Conversely, enterococcal bloodstream infection requires prompt clinical assessment, source investigation, and consideration of endocarditis, especially for E. faecalis. Deep or normally sterile-site specimens provide stronger evidence of pathogenicity than superficial swabs or surveillance cultures, although specimen quality and the possibility of contamination remain critical. Intra-abdominal isolation must be interpreted in relation to source control, severity, healthcare association, and polymicrobial growth. Species identification, susceptibility testing, and targeted therapy are essential because intrinsic cephalosporin resistance and acquired vancomycin resistance limit treatment options. A stepwise clinical–microbiological framework can reduce both missed invasive infections and unnecessary antibiotic exposure. Enterococci should neither be dismissed reflexively nor treated solely because a culture is positive; management must be driven by syndrome, specimen validity, host factors, and the strength of microbiological evidence.
ORIGINAL RESEARCH ARTICLE | Nov. 2, 2026
Comparative Assessment of the Antibacterial Potential of Curcumin and Tridax Procumbens Microsponge-Based Gel Formulations
Alexander Sekar, Manikandan Duraikannu, Maxcil Rajamanickam, Karthikeyan Chokkalingam
Page no 626-632 |
https://doi.org/10.36348/sjmps.2026.v12i11.002
The aim of the present study was to formulate, evaluate, and compare the antibacterial activities of topical gel formulations containing Tridax procumbens and curcumin-loaded microsponges. The microsponges were prepared using the quasi-emulsion solvent diffusion method, with ethyl cellulose as the polymer and polyvinyl alcohol as the stabilizer. The prepared microsponges were subsequently incorporated into a Carbopol-based gel to develop microsponge-loaded topical formulations. The formulations were evaluated for physicochemical parameters, including production yield, compatibility, surface morphology using scanning electron microscopy (SEM), pH, viscosity, spreadability, washability, and stability. SEM analysis revealed that the microsponges were spherical, porous, and uniformly distributed, indicating their potential suitability for controlled drug release. The pH values of the formulated gels were within the acceptable range for topical application, suggesting good compatibility with the skin. Antibacterial activity was evaluated using agar well diffusion method. Both Tridax procumbens and curcumin microsponge-based gels demonstrated notable antibacterial activity, with the curcumin-loaded microsponge gel exhibiting comparatively larger zones of inhibition against certain bacterial strains. The findings suggest that microsponge-based gel formulations may offer a promising approach to controlled topical drug delivery, with potential benefits in drug stability and patient compliance, along with improved antibacterial performance compared with conventional gel formulations. Further studies are required to establish their clinical efficacy and confirm their advantages over conventional topical preparations.
ORIGINAL RESEARCH ARTICLE | Nov. 5, 2026
Impact of Educational Intervention on Knowledge, Attitude and Practice of Pharmacovigilance, Materiovigilance and Haemovigilance among Final Year Medical and Paramedical Students: A Prospective Cross-Sectional Study
Binu K. M., H. Doddayya, V. Sougath Reddy, Adidurga Jogeshwar Rao, A. Gnaneshwari, Aaqib Qayoom, Boya Harshita, Sagnik Gosh
Page no 633-640 |
https://doi.org/10.36348/sjmps.2026.v12i11.003
Pharmacovigilance, Materiovigilance, and Haemovigilance together form the backbone of healthcare safety monitoring in India, yet their coverage in undergraduate curriculum remains inconsistent. This prospective cross-sectional study assessed the impact of a short structured educational session on knowledge, attitude, and practice of all three vigilance systems among 200 final-year medical and paramedical students at a tertiary care teaching hospital in Raichur, Karnataka. A validated pre-test/post-test questionnaire was administered before and after a 15-minute seminar; data were analyzed by the Wilcoxon Signed-Rank Test and Chisquare test (SPSS v20.0). The cohort was 56% female, with a mean age of 22.21 ± 1.87 years; pharmacy students made up 79% of participants. Haemovigilance showed the clearest benefit: knowledge improved significantly (p = 0.033) and practice improved highly significantly (p = 0.0002). Pharmacovigilance knowledge edged upward but did not reach significance (p = 0.052), while attitude fell sharply (p = 0.0001). In Materiovigilance, both knowledge (p = 0.035) and attitude (p = 0.032) declined significantly after the session, though all four practice items improved on Chi-square analysis. The declines in attitude scores likely reflect critical recalibration rather than genuine disengagement. A single short seminar can shift knowledge and practice in selected domains, but is insufficient for attitude change across all three. Regular, multi-session, curriculum-integrated vigilance training is needed to build the reporting culture that patient safety requires.
ORIGINAL RESEARCH ARTICLE | Nov. 7, 2026
Malignant Brenner Tumor of the Ovary Presenting with Hepatic Metastases: A Case Report and Systematic Review of Update Treatment Strategies and Outcomes
Mohammed Essam Mahroos, Ali Abdullah Alshehri, Duaa Salem Alkhayat
Page no 641-650 |
https://doi.org/10.36348/sjmps.2026.v12i11.004
Background: Malignant Brenner tumor (MBT) is an exceptionally rare epithelial ovarian neoplasm, accounting for less than 1% of malignant ovarian tumors. No prospective data exist, and systemic therapy is extrapolated from high-grade epithelial ovarian carcinoma. Case presentation: A 37-year-old woman presented with abdominal pain, bloating and altered bowel habit. CT showed a large sigmoid mass inseparable from the left ovary and multiple hepatic lesions; CA-125 was 797 U/mL. Image-guided liver biopsy showed poorly differentiated adenocarcinoma, and sigmoid biopsy showed undifferentiated carcinoma expressing p63 and GATA3, consistent with MBT of ovarian origin (FIGO stage IVB). After multidisciplinary review, palliative carboplatin (AUC 5) and paclitaxel (175 mg/m²) every 21 days were started. Nine days after cycle 2 she developed febrile neutropenia (ANC 0.22 × 10⁹/L) with hypotension and a lactate of 10 mmol/L, requiring 24 hours of intensive care; cultures were negative and she recovered with piperacillin–tazobactam and fluid resuscitation. Treatment resumed at reduced doses (carboplatin AUC 4, paclitaxel 150 mg/m²) with pegfilgrastim. CA-125 rose to 1,232 U/mL before cycle 2 and fell to 645 U/mL before cycle 3; CT after cycle 2 showed stable hepatic metastases and a mild response of the pelvic primary. Literature update: Following the PRISMA-based 2024 systematic review (115 cases, searched to 15 September 2023), a provisional update search identified four further patients with ovarian MBT meeting the review's diagnostic criteria, with five more awaiting full-text assessment. All included cases, and all pending cases with a reported stage, were stage I–II; none described stage IV disease or hepatic metastases. Conclusions: Diagnosing MBT on biopsy material alone is difficult and depends on integrating morphology and immunohistochemistry with exclusion of urothelial and colorectal primaries. Treatment evidence is limited to case reports, small series and registry data, and carboplatin–paclitaxel is the most commonly reported regimen. Genomic data suggest that MBT is usually microsatellite-stable without homologous recombination deficiency and frequently carries FGFR3 alterations, so comprehensive profiling is more informative than empirical PARP or checkpoint inhibition.
CASE REPORT | Nov. 7, 2026
Early-Onset Trastuzumab Deruxtecan–Associated Interstitial Lung Disease During First-Line Treatment of HER2-Positive Metastatic Breast Cancer with Hepatic Visceral Crisis: A Case Report and Systematic Review with Meta-Analysis
Mohammed Essam Mahroos, Sarah Khalid Alrasheed, Amer Sameer Zaheralliyali
Page no 651-660 |
https://doi.org/10.36348/sjmps.2026.v12i11.005
Background: Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody–drug conjugate (ADC) with substantial activity across HER2-expressing breast cancer. Interstitial lung disease (ILD)/pneumonitis is its most important adverse event of special interest and can be fatal. We report an early-onset, oxygen-requiring case and systematically review the incidence, timing, presentation, and management of T-DXd–associated ILD in breast cancer. Case presentation: A 47-year-old woman with de novo ER-negative, PR-negative, HER2-positive metastatic breast cancer (hepatic, pulmonary, and osseous metastases) and hepatic visceral crisis (total bilirubin 375 µmol/L) started T-DXd on 28 June 2026. After two cycles, bilirubin fell to 113 µmol/L and then normalised, with multisite radiological response. Approximately 5 weeks after the first dose she developed dyspnoea, non-productive cough, low-grade fever, tachycardia, and hypoxaemia (SpO₂ ≈88% on room air). CT pulmonary angiography excluded embolism and showed new bilateral ground-glass and consolidative opacities with interlobular septal thickening, while pulmonary metastases were regressing. Bronchoalveolar lavage (BAL) was negative for malignancy, fungi, and Pneumocystis jirovecii. Grade 3 T-DXd–associated ILD was diagnosed; T-DXd was permanently discontinued and prednisolone (≈1 mg/kg/day) plus empirical piperacillin–tazobactam and supplemental oxygen were started, with clinical stabilisation. Methods: Following PRISMA 2020, we searched PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, and major oncology congress proceedings to 31 October 2026 for prospective trials of T-DXd in breast cancer reporting ILD incidence and for case reports/series of T-DXd–associated ILD. Incidence was pooled with a DerSimonian–Laird random-effects model on the logit scale. Results: Eight prospective trials (3,341 T-DXd-treated patients) were pooled. Any-grade drug-related ILD occurred in 12.1% (95% CI 10.7–13.6; I² = 39%) and grade 5 ILD in 0.8% (95% CI 0.5–1.5). In metastatic disease the pooled incidence was 12.7% (11.4–14.0; I² = 0%); in HER2-positive metastatic disease, 13.1% (11.4–15.0). Case reports (7 patients) and national post-marketing data showed an organising-pneumonia–predominant imaging pattern, onset ranging from 2 to 9 cycles, frequent prolonged corticosteroid dependence, and use of cyclophosphamide, infliximab, mycophenolate, or tacrolimus in steroid-refractory cases. Conclusions: Roughly one in eight breast cancer patients receiving T-DXd develops ILD, and about 1% die of it. Onset can be early, and ILD can emerge during an excellent tumour response—discordant radiology (regressing nodules with new diffuse opacities) is a useful diagnostic clue. Structured respiratory surveillance, low threshold for CT, prompt exclusion of infection, permanent discontinuation for grade ≥2 events, and grade-appropriate corticosteroids remain central.
Keywords: Trastuzumab deruxtecan; interstitial lung disease; pneumonitis; HER2-positive breast cancer; antibody–drug conjugate; visceral crisis; systematic review; meta-analysis.
ORIGINAL RESEARCH ARTICLE | Nov. 11, 2026
Effectiveness of Primary Care Interventions to Reduce Antibiotic Prescribing for Acute Respiratory Infections: Systematic Review
Fai Alomair*, Nurah Alkhteeb, Jwaher Al Mulhim, Aisha Alamer, Jumana Alsultan, Norah Omar S. Alomar
Page no 661-672 |
https://doi.org/10.36348/sjmps.2026.v12i11.006
Background: Antimicrobial resistance represents one of the most consequential public health emergencies of the twenty-first century, driven predominantly by the inappropriate and excessive consumption of systemic antibiotics in ambulatory healthcare settings. Acute respiratory tract infections constitute the single most frequent diagnostic indication for outpatient medical consultations worldwide and account for the vast majority of unnecessary antibiotic prescriptions despite their overwhelmingly viral and self-limiting etiology. Although numerous stewardship strategies have been trialed in general practice and family medicine, comparative synthesis of their clinical effectiveness, safety, and behavioural mechanisms remains essential for guiding health policy. Objective: This systematic review aimed to evaluate and qualitatively synthesize evidence from randomized controlled trials investigating the effectiveness and clinical safety of primary care interventions designed to reduce inappropriate overall or broad-spectrum antibiotic prescribing for patients presenting with acute respiratory infections. Methods: A comprehensive systematic literature search was conducted across MEDLINE via PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science to identify randomized controlled trials and cluster randomized controlled trials published in peer-reviewed journals. Eligible studies evaluated clinician-targeted, patient-targeted, diagnostic point-of-care, behavioral, or health-system interventions implemented in primary care practices for acute upper or lower respiratory tract infections compared with usual care or alternative stewardship strategies. Methodological quality was appraised using the revised Cochrane Risk of Bias tool for randomized trials. Due to substantial heterogeneity across intervention modalities and outcome metrics, a structured thematic qualitative data synthesis was performed in accordance with PRISMA 2020 guidelines. Results: From 2,480 initially identified records, 1,868 unique citations were screened after deduplication, 74 full-text articles were evaluated for eligibility, and nine landmark randomized controlled trials encompassing more than 440,000 patient consultations across Europe and North America were included in the final qualitative synthesis. Point-of-care C-reactive protein testing and enhanced clinician communication skills training demonstrated pronounced, synergistic reductions in antibiotic prescribing ranging from 31% to 62% relative risk reductions. Shared decision-making training programs and delayed antibiotic prescribing strategies reduced patient antibiotic consumption by 25% to 64% compared with immediate prescribing. Multifaceted educational outreach, peer academic detailing with personalized audit and feedback, and behavioral economics nudges such as accountable justification and peer comparison significantly reduced both overall inappropriate prescribing and broad-spectrum antimicrobial selection without increasing hospital admissions, suppurative bacterial complications, or unplanned reconsultations. Conclusion: Multifaceted primary care interventions that combine diagnostic uncertainty reduction, structured clinician-patient communication, delayed prescribing safety nets, and socially anchored audit and feedback safely and substantially reduce unnecessary antibiotic prescribing for acute respiratory infections.